Volume 6, Issue 2 (May 2019)                   IJML 2019, 6(2): 131-137 | Back to browse issues page


XML Print


Department of pharmacology, Faculty of pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract:   (1466 Views)
Background and Aims: Because of the toxicity and side-effects of synthetic drugs, there is a growing interest in biomedical plants. The aim of this study was to evaluate in vitro antileishmanial activity of Carum copticum essential oil against Leishmania (L) major.
Materials and Methods: Nineteen experimental groups were designed to determine the effect of Carum copticum essential oil against L. major and compare it with Meglumine antimonite. Group 1 was the control group and included 200 µl of RPMI 1640 plus 2×105 cells/ml promastigotes. Groups 2-10 included the aforementioned substances plus 10 µl of 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2 and 3 µg/ml of Carum copticum essential oil respectively. Groups 11-19 were similar to groups 2-10 but Meglumine antimonite (0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2 and 3 µg/ml) was used instead of Carum copticum essential oil. All the experiments were repeated five times. After 8 hours, the antileishmanial activities of studied substances were determined.
Results: Up to concentration of 0.5 µg/ml, no effect was observed with both substances. In comparison to control group, at 1 and 2 µg/ml, Meglumine antimonite had no effect on Leishmaniasis (p>0.05) while Carum copticum essential oil significantly decreased Leishmaniasis viability (p<0.05). Moreover, at 3 µg/ml, both compounds significantly decreased Leishmaniasis viability (p<0.05). However, Carum copticum essential oil had substantially better Antileishmanial activity than the other.  
Conclusions: These results suggest that comparable concentrations, in vitro antileishmanial activity of Carum copticum essential oil is better than Meglumine antimonite.
Full-Text [PDF 403 kb]   (446 Downloads) |   |   Full-Text (HTML)  (591 Views)  
Type of Study: Research | Subject: Parasitology
Received: 2018/07/8 | Accepted: 2019/05/6 | Published: 2019/05/31

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.